Abstract: Objective: Chemotherapy resistance is the main reason for the poor prognosis of ovarian cancer. How endothelial lipase (LIPG) -mediated reprogramming of lipid metabolism regulates response to platinum-based chemotherapy remains incompletely elucidated ;Methods: Bioinformatics analysis combined with clinical samples (immunohistochemistry, quantitative real-time PCR, etc.) was used to evaluate LIPG expression, related molecular pathways (such as lipid metabolism), immune infiltration, prediction and prognostic value; Result: LIPG is associated with lipid metabolic reprogramming pathway and immune infiltration, and negatively correlated with overall survival and progression-free survival in ovarian cancer patients. Clinical samples showed that the expression level of LIPG protein was significantly higher in platinum-resistant patients than in platinum-sensitive patients;Conclusions: LIPG protein plays an important role in platinum resistance and poor prognosis of ovarian cancer, and its high expression may promote tumor immune escape by regulating lipid metabolism reprogramming. LIPG may be a novel biomarker for predicting response to chemotherapy.